Product Information
LETROZOLE 2.5 MG TABLET is a generic product labeled by Avet Pharmaceuticals Inc., priced at $0.1450 per EA under NDC 23155087510. Its NADAC has been published 121 times since Jun 12, 2024.
FDA first approved this application on Nov 14, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5 mg/1
Manufacturer
Avet Pharmaceuticals Inc.NDC
23155087510
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LETROZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA205869FDA Approved
11/14/2018
TE Code
AB
On Market Since
6/1/2023
Pharmacological Classes
Price Statistics
The NADAC for LETROZOLE 2.5 MG TABLET has been published 121 times since Jun 12, 2024, and over the history we have for it it has risen 15.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1450 per EA |
|---|---|
| All-time high | $0.1535 (Jul 15, 2026) |
| All-time low | $0.1225 (Jul 17, 2024) |
| 52-week high | $0.1535 |
| 52-week low | $0.1292 |
| Median price | $0.1422 |
| Average price | $0.1409 |
| Largest weekly change | +16.5% (Aug 21, 2024) |
| Weeks tracked | 121 |
| Tracking since | Jun 12, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 17% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Avet Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Letrozole Tablets market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LETROZOLE 2.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LETROZOLE 2.5 MG TABLET, manufactured by Avet Pharmaceuticals Inc., is $0.1450 per EA (NDC 23155087510), effective Sep 30, 2026.
How has the price of LETROZOLE 2.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for LETROZOLE 2.5 MG TABLET has risen 15.2%. It has been tracked across 121 weekly CMS publications since Jun 12, 2024.
What are the highest and lowest recorded NADAC prices for LETROZOLE 2.5 MG TABLET?
Since Jun 12, 2024, the NADAC for LETROZOLE 2.5 MG TABLET has ranged from a low of $0.1225 (Jul 17, 2024) to a high of $0.1535 (Jul 15, 2026), with a median of $0.1422 per EA.
Are there cheaper alternatives to LETROZOLE 2.5 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LETROZOLE 2.5 MG TABLET, is $0.1203 per EA — about 17% below LETROZOLE 2.5 MG TABLET.
Who manufactures LETROZOLE 2.5 MG TABLET?
LETROZOLE 2.5 MG TABLET (NDC 23155087510) is labeled by Avet Pharmaceuticals Inc., and CMS classifies it as a generic product.